

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

February 15, 2024

**CSO Daisuke Morishita receives the Minister of State for Science and Technology Policy Award at the 6th Japan Open Innovation Prize**

Kanagawa, Japan, February 15, 2024 – Chordia Therapeutics Inc. (Chordia) is pleased to announce that our CSO, Daisuke Morishita, received the "Minister of State for Science and Technology Policy Award" at the 6th Japan Open Innovation Awards organized by the Cabinet Office.

During the judging of the award, the company was highly evaluated as a new role model for the future of Japan's drug discovery ecosystem by creating a new anti-cancer drug, a MALT1 inhibitor, independently from major companies. The development was made possible through the cooperation of public and private funds, through industry-government-academia collaboration with universities and AMED. The company's successful out-licensing of the drug to pharmaceutical companies further solidified its commendable position.

Through collaboration with universities, research institutes, and companies in the healthcare industry, we will continue our efforts to reform the medical treatment of cancers for which there are still insufficient treatments through the creation of first-in-class drugs.

**About the 6th Japan Open Innovation Prize**

As international competition over the creation of innovation intensifies, a major challenge is to quickly implement the results of research and development and other activities in society, and to link them to the resolution of social needs and the creation of new value. As a way to achieve this, open innovation, which promotes new approaches by combining knowledge, technology, and management resources across organizational boundaries, is attracting attention.

In light of this situation, and in order to further promote open innovation in Japan, the "Japan Open Innovation Awards" are given to initiatives with high leadership and originality that are expected to serve as role models for the future.



JAPAN OPEN  
INNOVATION PRIZE

## Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

[ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)



---

### **About Chordia Therapeutics**

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia's lead asset, the CLK inhibitor CTX-712, is under Phase 1 clinical study in Japan and Phase 1/2 clinical study in the US. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017  
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,  
Kanagawa 251-0012, Japan  
Representative: Hiroshi Miyake, Representative Director  
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR, Mizobe: [ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)